Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Vascular endothelial growth factor Stories

2012-11-27 04:20:35

TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). According to the European Medicines Agency (EMA) approved Summary of Product Characteristics, EYLEA treatment is initiated with one 2 milligram (mg) injection per month for three consecutive months,...

2012-11-26 08:23:55

ROCKVILLE, Md., Nov. 26, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced today the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) The article, entitled "Predictive Biomarkers of Sensitivity to the Aurora and...

2012-11-20 08:27:15

NEW YORK, Nov. 20, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCBB: OHRP) today announced the addition of two prominent ophthalmologists to its Scientific Advisory Board ("SAB") comprised of leading retinal ophthalmology experts to assist in advancing the Squalamine eye drop program through clinical efficacy trials. Jeffrey S. Heier, M.D. of Ophthalmic Consultants of Boston, and Daniel Roth, M.D., of Retina Vitreous Center in New Jersey will be joining as members of the SAB. These highly...

2012-11-15 12:27:22

TORONTO, Nov. 15, 2012 /PRNewswire/ -- In response to the November 11, 2012 press release issued by the American Academy of Ophthalmology (AAO) Task Force on Genetic Testing, ArcticDx Inc. (Arctic) maintains that Macula Risk®, its laboratory developed test (LDT) for AMD, is of the highest standard and proven to add to the accuracy of clinical assessment alone in its intended use of risk stratification for AMD patients. While in general agreement with the Task Force's Recommendations for...

2012-11-14 08:31:33

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) EntreMed reported a net loss for the third quarter of 2012 of ($1.2 million), or ($0.05) per share. This compares with a net loss of ($1.3 million), or ($0.13) per...

2012-11-05 04:21:53

SOUTHAMPTON, England, November 5, 2012 /PRNewswire/ -- KalVista Pharmaceuticals ("KalVista") today announces it has won a GBP2.4 million grant from the Technology Strategy Board under the UK Government's GBP180 million Biomedical Catalyst funding initiative for research and development in the life sciences. KalVista will use the new funding to accelerate the development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME), the leading cause of...

2012-11-02 11:26:11

LUGANO, Switzerland, November 2, 2012 /PRNewswire/ -- 12th International AMD and Retina Congress in Prague, 2-3 Nov 2012 ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th AMD and Retina Congress in Prague. Following on from the 11th congress in Lisbon, which covered the whole spectrum of retinopathy, this year's meeting in the Czech Republic takes a significant step forward, demonstrating how international collaboration and exchange...

2012-10-18 15:22:19

TARRYTOWN, N.Y., Oct. 18, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed one-year results from the VIEW 1 and VIEW 2 Phase 3 studies of EYLEA (aflibercept) Injection were published online in the journal Ophthalmology ahead of a future print publication. The publication can be accessed at http://digitalreprints.elsevier.com/t/28599. "The article published today provides additional details about the VIEW 1 and VIEW 2 studies that demonstrated...

2012-10-15 07:28:52

INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab. The REGARD trial compared ramucirumab and best supportive care to placebo and best supportive care as a second-line...

2012-09-29 02:20:06

INDIANAPOLIS, Sept. 29, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Results were presented today during the Lung Cancer - Metastatic Poster Session at the ESMO 2012 Congress (European Society for Medical Oncology), 1:00 p.m. - 2:00 p.m. CET, in Vienna, Austria. Interim data for a study in chemotherapy-naive patients with advanced NSCLC treated with...